CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting

This educational activity will assist community oncology practices as they adopt bispecific antibodies for the treatment of patients with relapsed/refractory LBCL/DLBCL to deliver quality evidence-based care.